OR WAIT 15 SECS
The opioid crisis cost the U.S. billions. Find out the impact on the future economy.
The opioid epidemic cost the U.S. economy at least $631 billion from 2015 to 2018, according to a Society of Actuaries’ (SOA) analysis of non-medical opioid use during this timeframe.
In addition, the SOA report projected future costs of the opioid epidemic for 2019 based on three scenarios reflecting how the crisis may develop moving forward. Predictions resulted with a midpoint cost estimate of $188 billion and the low and high cost estimates ranging from $172 billion to $214 billion.
This study is the first from the SOA’s Mortality and Longevity Strategic Research Program, which builds on existing research examining the factors affecting models and mortality predictions, including the analysis of longevity trends.
Key findings from the study include the financial burden of the opioid epidemic across the following areas of the economy between 2015 and 2018:
Based on the SOA’s midpoint cost estimate for 2019 at $188 billion, and its low and high cost estimates ranging from $172 billion to $214 billion, the estimates reflect a potential range of outcomes for key assumptions such as the prevalence of opioid use disorder and the number of opioid overdose deaths in 2019. The estimates are intended to represent a few potential scenarios rather than the minimum or maximum of possible outcomes.
"As stakeholders seek to understand and address the opioid epidemic, this analysis provides insight into the tremendous impact across all areas of our economy,” says Dale Hall, FSA, CERA, MAAA, CFA and managing director of research with the Society of Actuaries. “Actuaries have long played a vital role in measuring population-level risks and will continue to work with the healthcare industry to evaluate the impact of the opioid epidemic on pricing, valuation and other crucial calculations moving forward.”
The SOA’s analysis is based on a range of data sources, including administrative claims data, federal surveys and databases, as well as prior peer-reviewed literature to determine the total economic burden.
However, the analysis does not include economic impacts for which there is a lack of adequate data, such as reductions in household (non-paid) productivity, reductions in on-the-job productivity (presenteeism) or reductions in quality of life for those impacted directly or indirectly by opioid use disorder.
The SOA will continue to analyze new data as it is available, to arm actuaries and external stakeholders with crucial insight into the financial impact of the opioid epidemic.
For additional information, including the full SOA analysis and report, visit www.soa.org/resources/research-reports/2019/econ-impact-non-medical-opioid-use/